BETH ISRAEL DEACONESS MEDICAL CENTER

Iovance Biotherapeutics has appointed Marc R. Theoret, M.D., former FDA Deputy Center Director, to the newly created position of Senior Vice President, Regulatory Strategy.

Biomerica has appointed Scott Madel as Chief Commercial Officer to accelerate commercialization of its inFoods IBS diagnostic test, bringing over 20 years of experience in laboratory testing and clinical diagnostics.

A major study analyzing over 265,000 sepsis patients found that statin treatment was associated with a 39% lower 28-day mortality rate compared to standard care alone.

The prevalence of depression among Americans aged 12 and older reached 13.1% during 2021-2023, marking a significant 60% increase from 8.2% in 2013-2014.

A comprehensive review of 301 clinical trials reveals only 10% of treatments for low back pain show evidence of effectiveness, with most providing only marginal relief compared to placebo.

Precision Neuroscience has received FDA 510(k) clearance for its Layer 7 Cortical Interface, marking the first full regulatory approval for a next-generation wireless brain-computer interface technology.

IMNN-101, a novel DNA-based COVID-19 vaccine, demonstrated a 2-4 fold increase in neutralizing antibody titers through Week 4 in Phase 1 trial participants.

Shape Memory Medical has announced the first European enrollment in their AAA-SHAPE pivotal trial, evaluating the IMPEDE-FX RapidFill device for improving abdominal aortic aneurysm outcomes during endovascular repair.

• Revalesio's Phase 2 RESCUE trial demonstrated that RNS60 significantly reduced infarct growth by 50% in acute ischemic stroke patients treated within 12 hours of symptom onset. • The study showed correlation between reduced brain tissue loss and meaningful improvements in functional outcomes, measured by modified Rankin Scale, Barthel Index, and NIH Stroke Scale. • The double-blind, placebo-controlled trial evaluated two doses of RNS60 in 82 patients undergoing endovascular thrombectomy, positioning it as a potential first significant stroke therapy advancement in decades.

• A groundbreaking study published in Nature Medicine reveals that physicians using AI language models demonstrated superior performance in patient care tasks compared to those using conventional resources. • Physicians utilizing AI spent approximately two minutes longer per case and showed reduced rates of mild-to-moderate harm potential (3.7% vs 5.3%) in their clinical decisions. • The research, led by BIDMC's AI Programs Director Dr. Adam Rodman, evaluated 92 physicians handling complex management reasoning tasks across five hypothetical patient cases.